animal health

Older dog and cat

BI aims to boost chronic disease portfolio post-Sanofi asset swap

On New Year’s Day, Sanofi and Boehringer Ingelheim closed a $12.5 billion asset swap that had been in the works for a year, giving the closely held Germany-based BI a suite of drugs to treat farm and companion animals. Here's what's next for the company, which had suffered some setbacks on the human side of the business prior to the deal.
Farming

UN names animal health as top priority for sustainable agriculture

The United Nations’ 2030 Agenda for Sustainable Development lays out a host of priorities including “food security and nutrition,” an ambitious plan to eliminate hunger and malnutrition. Now, the organization is defining the role of the world’s livestock caretakers in meeting that goal--naming animal health as a key part of its strategy.

VetStem submits trial data to FDA for canine stem cell therapy

VetStem Biopharma has treated more than 12,000 companion animals with stem cells removed from their own bodies and then reinjected to treat a variety of joint disorders, including osteoarthritis. Although the company has built its business around such “autologous” treatments, its executives have long believed that the real market opportunity lies in “allogeneic,” or off-the-shelf, stem cells.
Elderly Dog

Opko enters animal health market with big plans for oncology

Miami-based biotech Opko Health is branching out into animal health, joining one of the fastest growing segments of the industry: oncology. But the company--which has seen its share of struggles on the human health side of its business--will face plenty of competition as it embarks on its new endeavor.